Oric Pharmaceuticals
Idil Ulengin-Talkish is a Senior Scientist at ORIC Pharmaceuticals Inc. since March 2022, previously holding the position of Scientist. Prior experience includes serving as a Postdoctoral Researcher at Stanford University from April 2016 to March 2022 and at Carnegie Mellon University from August 2009 to February 2016. Idil completed a Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology at Carnegie Mellon University between 2009 and 2015. Prior educational qualifications include a Bachelor's degree in Biological Sciences and Bioengineering, alongside a Minor in Chemistry, from Sabancı University (2005-2009), and attending Uskudar Amerikan Academy for high school studies (2002-2005). Early research experience includes roles as a Summer Intern at the University of Heidelberg in 2008 and as an Undergraduate Researcher at Sabancı University.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.